Clinical pharmacology of intracarotid etoposide

Niramol Savaraj, Lynn G. Feun, Katherine Lu, Sidney Wallace, William S. Fields, Ti Li Loo

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Pharmacokinetics studies were performed in ten patients who received VP-16 by intracarotid infusion at 100-300 mg/m2. VP-16 was analyzed by high-pressure liquid chromatography. ESTRIP and NONLIN were used to characterize VP-16 pharmacokinetics. VP-16 disappeared biphasically, with a t1/2 β of 6.1±1.4 h; the total clearance was 26.8±2.8 ml/min/m2, and the Vss was 8.8±1.6 l/m2. The pharmacokinetics was not significantly different after administration by the IV route. However, at a lower dosage, <140 mg/m2, the half-life appears to be shorter. This may or may not be significant, since VP-16 pharmacokinetics is quite variable and the number of patients studied is relatively small. Overall, the brain and brain tumor do not appear to have any first-pass effect on VP-16 pharmacokinetics.

Original languageEnglish (US)
Pages (from-to)292-294
Number of pages3
JournalCancer Chemotherapy And Pharmacology
Issue number3
StatePublished - Apr 1 1986
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Clinical pharmacology of intracarotid etoposide'. Together they form a unique fingerprint.

Cite this